Incyte (NAS:INCY) Short-Term Debt & Capital Lease Obligation

: $11 Mil (As of Dec. 2022)

View and export this data going back to 1993. Start your Free Trial

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Incyte's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $11 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Incyte's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $30 Mil.

Incyte Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Incyte's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Short-Term Debt & Capital Lease Obligation

18.70

28.31

14.96

13.19

11.37

Incyte Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Short-Term Debt & Capital Lease Obligation																13.19	12.70	12.41	11.60	11.37

Incyte Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Incyte Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Incyte's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (NAS:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (NAS:INCY) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Executives

Susanne Schaffert	director	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Thomas Tray	officer: Principal Accounting Officer	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Katherine A High	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Edmund Harrigan	director
Michael James Morrissey	officer: EVP, Head of Tech. Operations	IN CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Jonathan Elliott Dickinson	officer: EVP, General Manager, Europe	CARE OF INCYTE CORPORATION, 1801 AUGUSTINE CUT OFF, WILMINGTON DE 19803
Christiana Stamoulis	officer: EVP & Chief Financial Officer	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Dashyant Dhanak	officer: EVP & Chief Scientific Officer	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Maria E Pasquale	officer: EVP & General Counsel	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Jacqualyn A Fouse	director	C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Vijay K Iyengar	officer: EVP GPS, BD, & Licensing	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Steven H Stein	officer: EVP & Chief Medical Officer	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul Trower	officer: VP, Finance & Prin Acc Officer	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Paul J Clancy	director	C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142